Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients
US9650429B2 · kind B2 · utility
19Cited by
0References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 9, 2015 |
| Grant date | May 16, 2017 |
| Priority date | — |
| Expiry date | Feb 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.